HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Bronchopulmonary Dysplasia

A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
Also Known As:
Dysplasia, Bronchopulmonary
Networked: 1957 relevant articles (71 outcomes, 213 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Lung Diseases (Lung Disease)
2. Birth Weight (Birth Weights)
3. Patent Ductus Arteriosus
4. Infection
5. Pulmonary Hypertension (Ayerza Syndrome)

Experts

1. Abman, Steven H: 23 articles (12/2015 - 08/2004)
2. Bhandari, Vineet: 22 articles (01/2015 - 05/2003)
3. Hallman, Mikko: 15 articles (10/2015 - 02/2003)
4. Doyle, Lex W: 14 articles (11/2015 - 05/2002)
5. Ehrenkranz, Richard A: 14 articles (12/2014 - 07/2005)
6. Yoder, Bradley A: 13 articles (01/2016 - 01/2003)
7. Ballard, Roberta A: 12 articles (12/2015 - 04/2003)
8. Jobe, Alan H: 12 articles (12/2015 - 11/2002)
9. Walsh, Michele C: 12 articles (03/2015 - 09/2003)
10. Carlo, Waldemar A: 12 articles (03/2015 - 10/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bronchopulmonary Dysplasia:
1. OxygenIBA
2. Dexamethasone (Maxidex)FDA LinkGeneric
3. Nitric Oxide (Nitrogen Monoxide)FDA Link
4. palivizumabFDA Link
5. Adrenal Cortex Hormones (Corticosteroids)IBA
6. SteroidsIBA
7. Caffeine (No Doz)FDA LinkGeneric
8. Vitamin A (Retinol)FDA LinkGeneric
9. Furosemide (Lasix)FDA LinkGeneric
10. GlucocorticoidsIBA

Therapies and Procedures

1. Artificial Respiration (Mechanical Ventilation)
2. Mechanical Ventilators (Ventilator)
3. Continuous Positive Airway Pressure
4. Neonatal Intensive Care
5. Catheters
12/01/2015 - "Newer management strategies with nasal cannula flows up to 4 L/min or more and 0.21 FiO2 at 36 weeks obscured classification of bronchopulmonary dysplasia status in 12.4% of infants. "
05/01/1989 - "When compared with PaO2, SpO2 values of 92% +/- 3% (mean +/- range) excluded all of the measured PaO2 values less than 45 mm Hg and greater than 100 mm Hg. SpO2-tcPO2 (transcutaneous PO2) and SpO2-PaO2 (catheter or percutaneous arterial PO2) correlations showed that bronchopulmonary dysplasia, percutaneous arterial sampling, and nipple feeding skewed the tcPO2 but not the PaO2 correlations with SpO2, indicating that SpO2 is not sensitive to peripheral factors that affect tcPO2. "
10/01/2014 - "Two randomized studies of surfactant administration using a thin catheter revealed no significant difference in the outcome of bronchopulmonary dysplasia but a potential reduction in the need for mechanical ventilation within 72 hours of birth when compared with standard care. "
01/01/2012 - "We also reduced bronchopulmonary dysplasia (30.2% vs 25.5%, P = .001), median days to regain birth weight (9 vs 8, P = .04), percutaneously placed central venous catheter use (54.8% vs 43.9%, P = .002), median antibiotic days (8 vs 6, P = .003), median total central line days (16 vs 15, P = .01), and median ventilator days (7 vs 5, P = .01). "
02/01/1985 - "A critically ill 20-month-old white male with severe bronchopulmonary dysplasia, cor pulmonale, and intolerance to enteral feeds, required a left percutaneous subclavian Broviac catheter. "